Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia; High-Risk and Very High-Risk Myelodysplastic Syndromes Intervention: Drug: SGR-2921 Sponsor: Schrödinger, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome | Research | Study